Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

86.01
+4.665.73%
Post-market: 86.010.00000.00%16:14 EDT
Volume:1.14M
Turnover:98.44M
Market Cap:5.58B
PE:-6.11
High:87.79
Open:81.01
Low:81.01
Close:81.35
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:1.15
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-535.87
PE(LYR):-183.00

Loading ...

RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP)

TIPRANKS
·
Oct 08

Mirum Pharmaceuticals (MIRM) Hits Its Primary Endpoint, Is The Stock Still Undervalued?

Simply Wall St.
·
Oct 07

Mirum Pharmaceuticals is Maintained at Buy by Citigroup

Dow Jones
·
Sep 30

TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Sep 29

Mirum Pharmaceuticals Price Target Raised to $195.00/Share from $140.00 by HC Wainwright & Co.

Dow Jones
·
Sep 29

Mirum's Liver Infection Drug Lowers Virus Levels in Late-Stage Study

Reuters
·
Sep 28

Mirum Pharmaceuticals, Inc. : Baird Raises Target Price to $130 from $123

THOMSON REUTERS
·
Sep 28

U.S. Stocks on the MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia

Reuters
·
Sep 28

Mirum Pharmaceuticals, - Phase 3 Primary Endpoint Achieved in Both Dose Arms at Week 24

THOMSON REUTERS
·
Sep 28

Mirum Pharmaceuticals Inc - Favorable Safety and Tolerability Profiles Observed; no New Safety Signals

THOMSON REUTERS
·
Sep 28

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 Azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

THOMSON REUTERS
·
Sep 28

Mirum Pharmaceuticals, - Brelovitug Well Tolerated Across Dose Groups with Consistent Safety Profile

THOMSON REUTERS
·
Sep 28

Mirum Rises on FDA Nod for Rare Bone Disorder Drug

Reuters
·
Sep 28

Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA

MT Newswires Live
·
Sep 28

Mirum to Share Phase 3 AZURE-1 Brelovitug Topline Data in Chronic Hepatitis Delta on Sept. 28 Investor Call

Reuters
·
Sep 28

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Sep 26

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26

Mirum Pharma CMO Rob Myers Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Mirum Grants Inducement Awards to 14 Hires, Including 28,512 Stock Options Priced at USD 100.61 Per Share

Reuters
·
Sep 15